

Manulife Investment Management and Trust Corporation
MANULIFE GLOBAL HEALTHCARE EQUITY FEEDER FUND (Bloomberg Ticker: MTPHGH4)
Key Information and Investment Disclosure Statement

As of December 31, 2025

Fund Facts

Classification:	Equity Fund	Net Asset Value per Unit (NAVPU):	PHP 78.7904
Launch Date:	January 18, 2021	Total Fund NAV:	PHP 1.17 billion
Minimum Investment:	PHP 1,000.00	Dealing Period:	Daily, up to 2:00PM
Additional Investment:	PHP 1,000.00	Redemption Settlement:	T+6
Minimum Holding Period:	Not applicable	Early Redemption Charge:	Not applicable

Fees*

Trust Fee:	1.7500% p.a.	Custody Fee:	0.0120% p.a.	Administration Fee:	0.0160% p.a.	External Auditor Fee:	0.0000%
Manulife IM (Philippines)	HSBC			HSBC		SGV & Co.	

* As a percentage of daily NAV.

Investment Objective and Strategy

The Fund is an equity UITF structured as a feeder fund that aims to maximize total return by investing all or substantially all of its assets in a collective investment scheme (CIS), the Target Fund. The Target Fund aims to provide medium to long term capital growth by investing mainly in equity and equity related securities of companies in health care. The Target Fund will mainly consist of equity and equity related securities in health care and related industries globally and which are listed on any stock exchange. The Target Fund may invest in companies which derive a significant portion of their earnings from medical and pharmaceutical products and services. The remaining assets of the Target Fund may include bonds and deposits. The Target Fund is the Manulife Global Fund – Healthcare Fund.

Client Suitability

A client profiling process should be performed prior to participating in the Fund to guide prospective investor if the Fund is suited to his/her investment objectives and risk tolerance. Clients are advised to read the Declaration of Trust/Plan Rules of the Fund, which may be obtained from the Trustee, before deciding to invest. The Manulife Global Healthcare Equity Feeder Fund is suitable for investors who are at least classified as aggressive based on their risk profile. To minimize risk and maximize returns, investors are recommended to stay invested in the Fund for at least five (5) years.

Key Risks and Risk Management

You should not invest in this Fund if you do not understand or are not comfortable with the accompanying risks. For a more comprehensive list of risks, please refer to the Risk Disclosure Statement.

Price Risk: The possibility for an investor to experience losses due to changes in market prices of securities.

Liquidity Risk: The possibility for an investor to experience losses due to inability to sell or convert assets into cash immediately or in instances where conversion to cash is possible but at a loss.

Credit Risk: The possibility for an investor to experience losses due to a borrower's failure to pay principal and/or interest in a timely manner. Investors may be exposed to higher degree of credit risk due to possible indirect holdings in below investment grade securities.

Reinvestment Risk: The possibility of having lower returns or earnings when maturing funds or the interest earnings of funds are reinvested.

Interest Rate Risk: The possibility for an investor to experience losses due to changes in interest rates.

Foreign Exchange Risk: This is the possibility for an investor to experience losses due to fluctuations in foreign exchange rates.

- THE UIT FUND IS A TRUST PRODUCT AND NOT A DEPOSIT ACCOUNT, AND IS NOT INSURED NOR GOVERNED BY THE PDIC;
- THE UIT FUND IS NOT AN OBLIGATION OF, NOR GUARANTEED, NOR INSURED BY THE TRUST ENTITY OR ITS AFFILIATES OR SUBSIDIARIES;
- DUE TO THE NATURE OF THE INVESTMENTS OF A UITF, THE RETURNS/YIELDS CANNOT BE GUARANTEED. HISTORICAL PERFORMANCE, WHEN PRESENTED, IS PURELY FOR REFERENCE PURPOSES AND IS NOT A GUARANTEE OF SIMILAR FUTURE PERFORMANCE;
- ANY LOSSES AND INCOME ARISING FROM MARKET FLUCTUATIONS AND PRICE VOLATILITY OF THE SECURITIES HELD BY THE UITF, EVEN IF INVESTED IN GOVERNMENT SECURITIES, ARE FOR THE ACCOUNT OF THE CLIENT. AS SUCH, THE UNITS OF PARTICIPATION OF THE CLIENT IN THE UITF, WHEN REDEEMED, MAY BE WORTH MORE OR WORTH LESS THAN HIS/HER INITIAL INVESTMENT/CONTRIBUTION;
- THE TRUSTEE IS NOT LIABLE FOR LOSSES UNLESS UPON WILLFUL DEFAULT, BAD FAITH, OR GROSS NEGLIGENCE;
- THE INVESTOR MUST READ THE COMPLETE DETAILS OF THE FUND IN THE UITF'S PLAN, MAKE HIS/HER OWN RISK ASSESSMENT, AND WHEN NECESSARY, SEEK AN INDEPENDENT/ PROFESSIONAL OPINION BEFORE MAKING AN INVESTMENT.

For more information, visit our website at <https://manulifeim.com.ph> or call (02) 8884-7000 or email us at phtrust@manulife.com. Manulife, Manulife Investment Management, and Manulife Investment Management & Block Design are trademarks of The Manufacturers Life Insurance Company and are used by it, and by its affiliates under license.

Manulife Investment Management and Trust Corporation

MANULIFE GLOBAL HEALTHCARE EQUITY FEEDER FUND (Bloomberg Ticker: MTPHGH4)

Fund Performance and Statistics (as of December 31, 2025)

(Purely for reference purposes and is not a guarantee of future results)

NAVPU Graph



NAVPU over the past 12 months

Highest	80.0047
Lowest	58.9291

Statistics

Volatility, Past 1 Year (%) ³	16.00
Sharpe Ratio ⁴	1.00
Information Ratio ⁵	0.81

*The Fund uses the MSCI World/Healthcare NR USD Index as a benchmark for performance comparison. This benchmark captures large and mid cap representation across Developed Markets countries. All securities in the index are classified in the Health Care as per the Global Industry Classification Standard. This is consistent with the investment objective and strategy of the fund to invest primarily in companies in health care and related industries globally or companies which derive a significant portion of their earnings from medical and pharmaceutical products and services. More detailed information can be found in the website of the benchmark provider at www.msci.com/equity-fact-sheet-search.

* MSCI World/Healthcare NR USD index

¹Returns are net of fees.

²Since Inception

³Volatility measures the degree to which the Fund fluctuates vis-à-vis its average return over a period of time.

⁴SharpeRatio is used to characterize how well the return of a Fund compensates the investor for the level of risk taken. The higher the number, the better.

⁵Information Ratio measures reward-to-risk efficiency of the portfolio relative to the benchmark. The higher the number, the higher the reward per unit of risk.

Cumulative Performance (%)¹

	1M	3M	6M	1Y	3Y	S.I. ²
Fund (Cumulative)	-0.37	16.04	26.10	22.06	30.35	63.92
Fund (Annualized)	n.a.	n.a.	n.a.	22.06	9.24	10.48
Benchmark* (Cumulative)	-0.48	11.80	18.98	16.79	27.20	60.51

Portfolio Composition

Allocation	% of Fund
Manulife Global Fund - Healthcare Fund	100.00
Sector Holdings [#]	% of Fund
Pharmaceuticals	37.11
Biotechnology	21.62
Healthcare Equipment & Supplies	18.81
Healthcare Providers & Services	14.30
Life Sciences Tools & Services	6.91
Cash & Cash Equivalents	1.25

Top Holdings[#]

	%
Eli Lilly and Company	9.86
AstraZeneca PLC	6.35
Johnson & Johnson	6.21
AbbVie, Inc.	5.88
Amgen Inc.	4.64
Medtronic Plc	4.55
McKesson Corporation	4.32
Stryker Corporation	4.18
Abbott Laboratories	3.51
Thermo Fisher Scientific Inc.	3.21

[#]Manulife Global Fund – Healthcare Fund

Outlook and Strategy

We believe that the defensive characteristics of the sector coupled with solid organic growth in select companies should provide strong performance over a full market cycle. In addition, capital markets access has improved dramatically in the back half of 2025 for biopharmaceutical companies which is a welcome change over the prior two years. We expect mergers and acquisitions to remain abundant as healthcare companies with strong balance sheets utilize excess capital to expand pipeline and product offerings.

Investment Policy / Prospective Investment

The Fund shall invest at least 90% of its assets in the Target Fund. The investment in the Target Fund shall not exceed 10% of the total net asset value of the Target Fund. The portion of the Fund that is not invested in the Target Fund, which shall not exceed 10% of the assets of the Fund, may be invested and/or reinvested in other investments allowed under the regulations issued by the BSP.

Related Party Transactions

The Fund currently has no investment with the Trustee's related parties. Subject to the approval of the Manulife Investment Management and Trust Corporation (Manulife IM (Philippines)) Board of Directors, all related party transactions will be conducted on an arm's length and best execution basis and within the approved limits.

Manulife IM (Philippines) and MIM (US) LLC are affiliates of Manulife Investment Management (MIM), the global asset management arm of Manulife. Manulife Investment Management has operations in 18 countries and territories.

Manulife IM (Philippines) is regulated by the Bangko Sentral ng Pilipinas. For any inquires and complaints to our services and products you may call our hotline: (632) 8884-7000, or send an email to phtrust@manulife.com. Manulife IM (Philippines) as Trustee / Investment Manager is regulated by the Bangko Sentral ng Pilipinas with telephone number (632) 8708-7087 and email address: consumeraffairs@bsp.gov.ph. To know your rights under BSP Circular No. 1160 (Regulations on Financial Consumer Protection), please access a copy at the BSP website (www.bsp.gov.ph).